Phenotypic variation in xenobiotic metabolism and adverse environmental response: focus on sulfur-dependent detoxification pathways.
Proper bodily response to environmental toxicants presumably requires proper function of the xenobiotic (foreign chemical) detoxification pathways. Links between phenotypic variations in xenobiotic metabolism and adverse environmental response have long been sought. Metabolism of the drug S-carboxymethyl-L-cysteine (SCMC) is polymorphous in the population, having a bimodal distribution of metabolites, 2.5% of the general population are thought to be nonmetabolizers. The researchers developing this data feel this implies a polymorphism in sulfoxidation of the amino acid cysteine to sulfate. While this interpretation is somewhat controversial, these metabolic differences reflected may have significant effects. Additionally, a significant number of individuals with environmental intolerance or chronic disease have impaired sulfation of phenolic xenobiotics. This impairment is demonstrated with the probe drug acetaminophen and is presumably due to starvation of the sulfotransferases for sulfate substrate. Reduced metabolism of SCMC has been found with increased frequency in individuals with several degenerative neurological and immunological conditions and drug intolerances, including Alzheimer's disease, Parkinson's disease, motor neuron disease, rheumatoid arthritis, and delayed food sensitivity. Impaired sulfation has been found in many of these conditions, and preliminary data suggests that it may be important in multiple chemical sensitivities and diet responsive autism. In addition, impaired sulfation may be relevant to intolerance of phenol, tyramine, and phenylic food constituents, and it may be a factor in the success of the Feingold diet. These studies indicate the need for the development of genetic and functional tests of xenobiotic metabolism as tools for further research in epidemiology and risk assessment.
McFadden
S A
SA
Independent Research Advocates, Dallas, TX 75206, USA.
D002233:Carbocysteine / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D004785:Environmental Pollutants / Q000009:adverse effects / Q000493:pharmacokinetics*; D014644:Genetic Variation; D006801:Humans; D008658:Inactivation, Metabolic; D018777:Multiple Chemical Sensitivity / Q000209:etiology / Q000235:genetics / Q000378:metabolism; D010641:Phenotype; D013455:Sulfur / Q000378:metabolism*; D015262:Xenobiotics / Q000009:adverse effects / Q000493:pharmacokinetics*
D004785:Environmental Pollutants; D015262:Xenobiotics; C020249:S-carboxymethylthiocysteine; D013455:Sulfur; D002233:Carbocysteine